Welcome to our dedicated page for Selecta Biosciences news (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on Selecta Biosciences stock.
Selecta Biosciences, Inc. (symbol: SELB) is a clinical-stage biopharmaceutical company dedicated to enhancing the efficacy of biologic therapies by reducing unwanted immune responses. The company's innovative approach leverages its proprietary tolerogenic Synthetic Vaccine Particles (SVP™) technology, which is designed to enable a wide range of biologics, particularly for rare and serious diseases that lack effective treatment options.
Selecta's current pipeline features SVP-enabled enzyme, oncology, and gene therapies. Leading the pipeline is SEL-212, a promising candidate in Phase 2 trials targeting severe gout. SEL-212 aims to alleviate debilitating symptoms such as flares and gouty arthritis, offering much-needed relief to patients. Another noteworthy candidate is SEL-403, a combination therapy comprising SVP-Rapamycin and LMB-100, which entered Phase 1 trials in 2018 for treating malignant pleural or peritoneal mesothelioma.
In addition to enzyme and oncology therapies, Selecta is developing gene therapy product candidates designed for rare metabolic disorders. These candidates hold the potential to enable repeat dosing and long-term efficacy. The company’s research endeavors are backed by a series of collaborations and partnerships that bolster its scientific and commercial capabilities.
The company's latest news highlights significant progress in its clinical trials and partnerships. Notable developments include updates on the potential of its Descartes-08 and Descartes-15 therapies to treat myasthenia gravis and other autoimmune diseases, as well as advancements in RNA Armory® technology.
Selecta continues to focus on mitigating risks inherent in clinical trials, regulatory processes, and funding requirements. The company's strategic initiatives and forward-looking statements are guided by its commitment to addressing unmet medical needs and bringing innovative therapies to market.
Selecta Biosciences (Nasdaq: SELB) and Ginkgo Bioworks (NYSE: DNA) announced a collaboration on January 10, 2022, to develop next-generation viral capsids for gene therapy. This partnership combines Selecta's ImmTOR platform with Ginkgo's cell programming technology to enhance transduction, tissue tropism, and reduce immunogenicity. Ginkgo will engineer the capsids, while Selecta handles pre-clinical and clinical studies. Financially, Ginkgo could receive up to $1.1 billion in total payments, including milestone payments in Selecta stock and royalties.
WATERTOWN, Mass., Jan. 05, 2022 - Selecta Biosciences (NASDAQ: SELB) announced a corporate update at the H.C. Wainwright BioConnect Conference, taking place virtually from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7 a.m. ET via the conference portal. Selecta is focused on developing tolerogenic therapies through its ImmTOR™ platform, aimed at mitigating unwanted immune responses. The company has various enzyme and gene therapy programs in its pipeline, which could enhance biologic therapies and address autoimmune diseases.
On December 29, 2021, Selecta Biosciences, Inc. (NASDAQ: SELB) announced its participation in the LifeSci Partners 11th Annual Corporate Access Event, scheduled for January 5-7, 2022. The company will take part in a panel discussion titled “Gene Therapy: Reaching its Full Potential” on January 6, 2022, at 11:00 AM ET. Investors can access the live webcast via the provided link. Selecta is known for its ImmTOR™ platform, which develops therapies aimed at mitigating immune responses and enhancing therapies for autoimmune diseases and gene therapy redosing.
Selecta Biosciences (NASDAQ: SELB) and Sobi have completed enrollment for the DISSOLVE I study, part of the Phase 3 DISSOLVE program for SEL-212, aimed at treating chronic refractory gout. This program evaluates SEL-212's efficacy and safety, with top-line results expected in H2 2022. SEL-212 combines Selecta’s ImmTOR platform with pegadricase to sustain uric acid levels, potentially reducing gout flares. Gout affects over 8.3 million in the U.S., with about 160,000 suffering from chronic refractory gout, a debilitating condition.
Selecta Biosciences (NASDAQ: SELB) has announced a clinical hold on its Phase 1/2 trial for SEL-302, addressing methylmalonic acidemia. The U.S. FDA issued this hold on November 23, 2021, citing questions related to chemistry, manufacturing, and controls (CMC) for the MMA-101 component. Notably, there were no clinical or pre-clinical issues raised in the FDA communication. The trial has not begun, and no patients will receive treatment until all concerns are resolved. Selecta has committed to working swiftly with the FDA to address these questions.
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology firm, announced its participation in the Jefferies Virtual London Healthcare Conference on November 18-19, 2021. The company will provide a corporate update and engage in one-on-one investor meetings. The presentation is scheduled for November 18 at 8:00 a.m. GMT (3:00 a.m. EST). Interested parties can access the live webcast and subsequent archived version through Selecta's official website.
Selecta Biosciences (NASDAQ: SELB) announced strategic advancements in its ImmTOR platform with four new collaborations aimed at enhancing gene therapies. The company reported a significant revenue increase to $24.4 million for Q3 2021, largely due to its partnership with Sobi. However, net loss rose to $17.9 million. Selecta is progressing in its clinical pipeline, including SEL-399's first-in-human trial, with further IND filings anticipated in 2022. With approximately $140 million in cash, the company expects financial stability into Q2 2023.
Selecta Biosciences (NASDAQ: SELB) announced encouraging results from its Phase I study using the ImmTOR™ platform in gene therapies. At day 30, 100% of subjects receiving a 0.3 mg/kg ImmTOR dose exhibited neutralizing antibody (NAb) titers of ≤ 1:25, significantly lower than controls. The study's findings suggest ImmTOR may mitigate the formation of NAbs against AAV8 capsids, potentially allowing for the re-dosing of gene therapies. Selecta plans to advance its gene therapy pipeline and evaluate partnership opportunities while awaiting FDA clearance for further trials.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced a conference call scheduled for November 9, 2021, to discuss its financial results for Q3 2021, ended September 30, and provide a business update. Participants can join via telephone or access the webcast through the company’s website. Selecta focuses on developing tolerogenic therapies using its ImmTOR™ platform, aimed at improving the efficacy of biologic treatments and restoring immune tolerance in autoimmune diseases.
On October 26, 2021, Selecta Biosciences (Nasdaq: SELB) announced a strategic collaboration with Ginkgo Bioworks (NYSE: DNA) to develop therapeutic enzymes aimed at treating autoimmune diseases. This partnership combines Selecta's ImmTOR technology with Ginkgo's enzyme discovery platform, potentially enhancing the efficacy of biologic therapies. Selecta could receive up to $85 million in milestone payments, including cash and stock. The collaboration is expected to expedite Selecta's pipeline expansion and improve patient outcomes.
FAQ
What is the market cap of Selecta Biosciences (SELB)?
What does Selecta Biosciences, Inc. specialize in?
What is SEL-212?
What is the significance of SVP™ technology?
What are the current projects in Selecta's pipeline?
What recent achievements has Selecta Biosciences made?
What partnerships does Selecta Biosciences have?
What is SEL-403?
How does Selecta Biosciences address risks in clinical trials?
What are the potential applications of Selecta's gene therapy candidates?
What are the key developments in Selecta's latest news?
